Literature DB >> 25534433

Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes.

Ewa Terczyńska-Dyla1, Stephanie Bibert2, Francois H T Duong3, Ilona Krol3, Sanne Jørgensen1, Emilie Collinet2, Zoltán Kutalik4, Vincent Aubert5, Andreas Cerny6, Laurent Kaiser7, Raffaele Malinverni8, Alessandra Mangia9, Darius Moradpour10, Beat Müllhaupt11, Francesco Negro12, Rosanna Santoro9, David Semela13, Nasser Semmo14, Markus H Heim3, Pierre-Yves Bochud2, Rune Hartmann1.   

Abstract

Hepatitis C virus (HCV) infections are the major cause of chronic liver disease, cirrhosis and hepatocellular carcinoma worldwide. Both spontaneous and treatment-induced clearance of HCV depend on genetic variation within the interferon-lambda locus, but until now no clear causal relationship has been established. Here we demonstrate that an amino-acid substitution in the IFNλ4 protein changing a proline at position 70 to a serine (P70S) substantially alters its antiviral activity. Patients harbouring the impaired IFNλ4-S70 variant display lower interferon-stimulated gene (ISG) expression levels, better treatment response rates and better spontaneous clearance rates, compared with patients coding for the fully active IFNλ4-P70 variant. Altogether, these data provide evidence supporting a role for the active IFNλ4 protein as the driver of high hepatic ISG expression as well as the cause of poor HCV clearance.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25534433     DOI: 10.1038/ncomms6699

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  34 in total

Review 1.  Acute hepatitis C: current status and remaining challenges.

Authors:  Teresa Santantonio; Johannes Wiegand; J Tilman Gerlach
Journal:  J Hepatol       Date:  2008-07-17       Impact factor: 25.083

2.  Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43.

Authors:  Magdalena Sarasin-Filipowicz; Xueya Wang; Ming Yan; Francois H T Duong; Valeria Poli; Douglas J Hilton; Dong-Er Zhang; Markus H Heim
Journal:  Mol Cell Biol       Date:  2009-06-29       Impact factor: 4.272

Review 3.  IL28B in the era of direct-acting antivirals for hepatitis C.

Authors:  Andrew J Muir
Journal:  J Clin Gastroenterol       Date:  2013-03       Impact factor: 3.062

4.  Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.

Authors:  Masao Honda; Akito Sakai; Tatsuya Yamashita; Yasunari Nakamoto; Eishiro Mizukoshi; Yoshio Sakai; Taro Yamashita; Mikiko Nakamura; Takayoshi Shirasaki; Katsuhisa Horimoto; Yasuhito Tanaka; Katsushi Tokunaga; Masashi Mizokami; Shuichi Kaneko
Journal:  Gastroenterology       Date:  2010-04-29       Impact factor: 22.682

Review 5.  25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end.

Authors:  Markus H Heim
Journal:  Nat Rev Immunol       Date:  2013-06-07       Impact factor: 53.106

6.  Human interferon-lambda3 is a potent member of the type III interferon family.

Authors:  C Dellgren; H H Gad; O J Hamming; J Melchjorsen; R Hartmann
Journal:  Genes Immun       Date:  2008-11-06       Impact factor: 2.676

7.  Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C.

Authors:  T Asselah; I Bieche; S Narguet; A Sabbagh; I Laurendeau; M-P Ripault; N Boyer; M Martinot-Peignoux; D Valla; M Vidaud; P Marcellin
Journal:  Gut       Date:  2007-09-25       Impact factor: 23.059

8.  IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.

Authors:  Vijayaprakash Suppiah; Max Moldovan; Golo Ahlenstiel; Thomas Berg; Martin Weltman; Maria Lorena Abate; Margaret Bassendine; Ulrich Spengler; Gregory J Dore; Elizabeth Powell; Stephen Riordan; David Sheridan; Antonina Smedile; Vincenzo Fragomeli; Tobias Müller; Melanie Bahlo; Graeme J Stewart; David R Booth; Jacob George
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

9.  USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon α response.

Authors:  Véronique François-Newton; Gabriel Magno de Freitas Almeida; Béatrice Payelle-Brogard; Danièle Monneron; Lydiane Pichard-Garcia; Jacob Piehler; Sandra Pellegrini; Gilles Uzé
Journal:  PLoS One       Date:  2011-07-14       Impact factor: 3.240

10.  Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.

Authors:  David L Thomas; Chloe L Thio; Maureen P Martin; Ying Qi; Dongliang Ge; Colm O'Huigin; Judith Kidd; Kenneth Kidd; Salim I Khakoo; Graeme Alexander; James J Goedert; Gregory D Kirk; Sharyne M Donfield; Hugo R Rosen; Leslie H Tobler; Michael P Busch; John G McHutchison; David B Goldstein; Mary Carrington
Journal:  Nature       Date:  2009-10-08       Impact factor: 49.962

View more
  59 in total

1.  Interferon λ 3 and 4 Genotyping Using High-Resolution Melt Curve Analysis Suitable for Multiple Clinical Sample Types.

Authors:  François M J Lamoury; Sofia Bartlett; Brendan Jacka; Behzad Hajarizadeh; Jason Grebely; Gail V Matthews; Gregory J Dore; Tanya L Applegate
Journal:  J Mol Diagn       Date:  2015-07-04       Impact factor: 5.568

2.  Spontaneous Clearance of the Hepatitis C Virus Among Men Who Have Sex With Men.

Authors:  Eric C Seaberg; Mallory D Witt; Lisa P Jacobson; Roger Detels; Charles R Rinaldo; Joseph B Margolick; Stephen Young; John P Phair; Chloe L Thio
Journal:  Clin Infect Dis       Date:  2015-07-14       Impact factor: 9.079

Review 3.  Contribution of type III interferons to antiviral immunity: location, location, location.

Authors:  Sergei V Kotenko; Joan E Durbin
Journal:  J Biol Chem       Date:  2017-03-13       Impact factor: 5.157

4.  The IFNL4 Gene Is a Noncanonical Interferon Gene with a Unique but Evolutionarily Conserved Regulation.

Authors:  Hao Zhou; Michelle Møhlenberg; Ewa Terczyńska-Dyla; Kasper Grønbjerg Winther; Nanna Hougaard Hansen; Johan Vad-Nielsen; Laura Laloli; Ronald Dijkman; Anders Lade Nielsen; Hans Henrik Gad; Rune Hartmann
Journal:  J Virol       Date:  2020-02-14       Impact factor: 5.103

5.  A multifaceted computational report on the variants effect on KIR2DL3 and IFNL3 candidate gene in HCV clearance.

Authors:  Pratichi Singh; J Febin Prabhu Dass
Journal:  Mol Biol Rep       Date:  2016-07-26       Impact factor: 2.316

6.  Genetic Variation at IFNL4 Influences Extrahepatic Interferon-Stimulated Gene Expression in Chronic HCV Patients.

Authors:  Brad R Rosenberg; Catherine A Freije; Naoko Imanaka; Spencer T Chen; Jennifer L Eitson; Rachel Caron; Skyler A Uhl; Marija Zeremski; Andrew Talal; Ira M Jacobson; Charles M Rice; John W Schoggins
Journal:  J Infect Dis       Date:  2018-01-30       Impact factor: 5.226

7.  SOCS1 is an inducible negative regulator of interferon λ (IFN-λ)-induced gene expression in vivo.

Authors:  Tanja Blumer; Mairene Coto-Llerena; Francois H T Duong; Markus H Heim
Journal:  J Biol Chem       Date:  2017-09-12       Impact factor: 5.157

Review 8.  Human Genetic Determinants of Viral Diseases.

Authors:  Adam D Kenney; James A Dowdle; Leonia Bozzacco; Temet M McMichael; Corine St Gelais; Amanda R Panfil; Yan Sun; Larry S Schlesinger; Matthew Z Anderson; Patrick L Green; Carolina B López; Brad R Rosenberg; Li Wu; Jacob S Yount
Journal:  Annu Rev Genet       Date:  2017-08-30       Impact factor: 16.830

9.  Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNα.

Authors:  Elisavet Serti; Heiyoung Park; Meghan Keane; Ashley C O'Keefe; Elenita Rivera; T Jake Liang; Marc Ghany; Barbara Rehermann
Journal:  Gut       Date:  2016-01-04       Impact factor: 23.059

Review 10.  Beyond autophagy: New roles for ULK1 in immune signaling and interferon responses.

Authors:  Diana Saleiro; Ewa M Kosciuczuk; Leonidas C Platanias
Journal:  Cytokine Growth Factor Rev       Date:  2016-04-01       Impact factor: 7.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.